Clinical Scorecard: Commemorating 50 Years of Progress in Blood and Marrow Transplantation: A Tribute to EBMT's Legacy

At a Glance

Key Highlights

• EBMT was founded in 1974 to promote collaboration and data sharing among European BMT teams, fostering advances in transplantation.
• Pioneering work established the importance of HLA compatibility, conditioning regimens, and immunosuppressive therapies to improve transplant outcomes.
• Introduction of reduced-intensity conditioning and cyclosporine-A significantly decreased transplant-related toxicity and GVHD incidence.

Guideline-Based Recommendations

Diagnosis

• Identify patients with hematological diseases who may benefit from BMT based on disease status and donor availability.
• Perform HLA typing to select compatible donors, preferably HLA identical siblings.

Management

• Use conditioning regimens such as total body irradiation (TBI) combined with cyclophosphamide (CY) or busulfan (BU) and CY to prepare patients for transplantation.
• Administer immunosuppressive agents including anti-thymocyte globulin (ATG) and cyclosporine-A to prevent and treat graft versus host disease (GVHD).
• Consider reduced-intensity conditioning regimens to decrease toxicity, especially in older patients.

Monitoring & Follow-up

• Monitor for engraftment success and chimerism post-transplant.
• Regularly assess for signs and severity of acute and chronic GVHD.
• Surveil for infections, including opportunistic infections such as herpes zoster.

Risks

• High risk of acute and chronic GVHD, which can be life-threatening.
• Transplant-related mortality ranging from 30% to 50% in early experience.
• Infections due to immunosuppression post-transplant.

Patient & Prescribing Data

Patients undergoing hematopoietic cell transplantation for hematological malignancies and aplastic anemia

Use of HLA identical sibling donors and optimized conditioning regimens improves remission rates; immunosuppressive therapies reduce GVHD incidence and severity; reduced-intensity conditioning expands eligibility to older patients.

Clinical Best Practices

• Foster multidisciplinary collaboration and data sharing to improve transplant protocols and outcomes.
• Select donors based on HLA compatibility to minimize rejection and GVHD.
• Tailor conditioning regimens to patient age and comorbidities to balance efficacy and toxicity.
• Implement prophylactic and therapeutic strategies for GVHD and infection management.
• Engage in continuous monitoring of transplant recipients for early detection of complications.

References

• EBMT official website
• Bortin G. Bone marrow transplantation: early clinical experience
• Mathé G. First human allogeneic BMT and clinical observations
• Speck B. Use of ATG in aplastic anemia
• Dausset J. Discovery of HLA and its role in transplantation
• Thomas ED et al. Development of conditioning regimens and GVHD prevention